Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 411Lymphoma 304Carcinoma, Non-Small-Cell Lung 262Melanoma 255Precursor Cell Lymphoblastic Leukemia-Lymphoma 251Prostatic Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 242Leukemia, Myeloid, Acute 222Lung Neoplasms 215Neoplasms 209Colonic Neoplasms 209Lymphoma, Non-Hodgkin 207Lymphoma, Large B-Cell, Diffuse 204Leukemia 200Multiple Myeloma 197Lymphoma, Follicular 197Colorectal Neoplasms 190Rectal Neoplasms 188Ovarian Neoplasms 184Burkitt Lymphoma 179Brain Neoplasms 171Neoplasm Metastasis 166Lymphoma, Mantle-Cell 163Carcinoma, Renal Cell 163Glioblastoma 161Sarcoma 156Pancreatic Neoplasms 147Lymphoma, B-Cell, Marginal Zone 143Unspecified Adult Solid Tumor, Protocol Specific 138Gliosarcoma 133

Interventions

ruxolitinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Interventional × Hypereosinophilic Syndrome × Clear all
NCT00044304 2026-03-16

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
70 enrolled
Myeloid

Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡